The modern management of severe aplastic anaemia

British Journal of Haematology

Volumn 110, Issue 1, 2000, Pages 41-53

  Ball, S E ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Antithymocyte globulin; Aplastic anaemia; Bone marrow transplantation; Late clonal disorders; Paroxysmal nocturnal haemoglobinuria

Indexed keywords

ANDROGEN; ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; INTERLEUKIN 6; STEM CELL FACTOR; THROMBOPOIETIN; THYMOCYTE ANTIBODY;

ANEMIA; APLASTIC ANEMIA; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG MEGADOSE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PREGNANCY; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; THROMBOCYTOPENIA;

ALGORITHMS; ANEMIA, APLASTIC; ANTILYMPHOCYTE SERUM; BONE MARROW TRANSPLANTATION; DIAGNOSIS, DIFFERENTIAL; FEMALE; GRAFT VS HOST DISEASE; HEMOGLOBINURIA, PAROXYSMAL; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSION; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PROGNOSIS; RISK FACTORS; SPLENECTOMY;

EID: 0033887731     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02081.x     Document Type: Review

References (124)

1. Pregnancy associated aplastic anaemia: A report of five cases and review of current management
2. The bone marrow failure syndromes
3. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome
4. Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia
5. Aetiology of severe aplastic anaemia and outcome after allogeneic bone marrow transplantation of immunosuppressive therapy
6. Bone marrow transplantation for severe aplastic anemia from HLA identical siblings
7. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): A report of the EBMT SAA Working Party
8. Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: A randomized trial from the EBMT SAA working party
9. Collection of peripheral blood hematopoietic progenitors (PBHP) from patients with severe aplastic anemia (SAA) after prolonged administration of granulocyte colony-stimulating factor
10. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): A pilot study of the EBMT SAA Working Party
11. Progessive telomere shortening in aplastic anemia
12. Gamma-irradiation of pretransplant blood transfusions from unrelated donors prevents sensitization to minor histocompatibility antigens on dog leukocyte antigen-identical canine marrow grafts
13. Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: A multicenter randomized controlled study
14. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene
15. The aplastic presentation of childhood leukaemia: A feature of common-ALL
16. Complete remission in severe aplastic anemia after high dose cyclophosphamide without bone marrow transplantation
17. Selection of patients for bone marrow transplantation in severe aplastic anaemia
18. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia
19. Antithymocyte globulin treatment in patients with aplastic anaemia: A prospective randomized trial
20. Do androgens enhance the response to antithymocyte globulin in patients with aplastic anemia? A prospective randomized trial
21. Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage-colony-stimulating factor
22. Ecstasy-induced very severe aplastic anemia complicated by invasive pulmonary mucormycosis treated with allogeneic peripheral blood progenitor cell transplant
23. Nutritional status and growth after bone marrow transplantation (BMT) during childhood: EBMT late effects working party retrospective data
24. Riddle: What do aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH) and 'hypoplastic' leukemia have in common?
25. Aplastic anaemia in the Northern Region 1971-78 and follow-up of long term survivors
26. The incidence and significance of fevers during treatment with antithymocyte globulin for aplastic anaemia
27. Modification of immunogenicity of transfusion products
28. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: A joint Seattle and Paris analysis of results in 700 patients
29. Long-term outcome after marrow transplantation for severe aplastic anemia
30. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy
31. Deficiency of glycosylphosphatidyl inositol-anchored proteins in patients with aplastic anaemia does not affect response to immunosuppressive therapy
32. Evolution of acquired severe aplastic anaemia to myelodysplasia and subsequent leukaemia in adults
33. Long-term follow-up of severe aplastic anaemia patients treated with antithymocytic globulin
34. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy
35. Hairy cell leukaemia presenting as aplastic anaemia
36. Primary treatment of acquired aplastic anemia: Outcomes with bone marrow transplantation and immunosuppressive therapy
37. Late graft failure 8 years after first bone marrow transplantation for severe acquired aplastic anemia
38. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes
39. Unrelated donor bone marrow transplantation for bone marrow failure (Abstract)
40. Peripheral blood picture in primary hypocellular refractory anemia and idiopathic acquired aplastic anemia: An additional tool for differential diagnosis
41. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine
42. Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): The SAA 94 experience
43. Effects of recombinant human interleukin-3 in aplastic anemia
44. Abnormal cytogenetic clones in patients with aplastic anaemia: Response to immunosuppressive therapy
45. The evidence-based analysis of treatment for chronic myeloid leukemia: An introduction to its methods and clinical implications
46. Results of immunosuppression in 170 cases of severe aplastic anaemia
47. Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia
48. European results of unrelated cord blood transplants
49. Treatment of Fanconi's anemia
50. Biologic characteristics of patients with hypocellular myelodysplastic syndromes
51. Apoptosis and its role in the myelodysplastic syndromes: Implications for disease natural history and treatment
52. Allogeneic stem cell transplantation for Fanconi Anaemia
53. A phase I/II trial of recombinant granolocyte-macrophage colony-stimulating factor for children with aplastic anemia
54. Bone marrow transplantation for severe aplastic anemia: The Barcelona Hospital Clinic experience
55. Natural history of paroxysmal nocturnal hemoglobinuria
56. Results of transplanting bone marrow from genetically identical twins into patients with aplastic anemia
57. Fertility, pregnancies and offspring complications after bone marrow transplantation
58. Apoptosis resistance of blood cells from patients with paroxysmal nocturnal hemoglobniuria, aplastic anemia, and myelodysplastic syndrome
59. A prospective study of factors determining the outcome of unrelated bone marrow donor searches: Report from the International Marrow Unrelated Search and Transplant Study Working Group on behalf of collaborating centres
60. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia
61. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow
62. Long-term administration of G-CSP for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults
63. Effect of androgens on the response to antithymocyte globulin in patients with aplastic anaemia
64. Pilot study of HLA alloimmunization after transfusion with pre-storage leucodepleted blood products in aplastic anaemia
65. Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: A multivariate analysis of data from 264 cases
66. Myelodysplasia and leukemia after treatment of aplastic anemia with G-CSF
67. Successful autologous transplantation in a patient with severe aplastic anemia (SAA)
68. Trilineage responses seen with stem cell factor (STEMGEN; SCF) and Filgrastim (G-CSF) treatment in aplastic anaemia patients (Abstract)
69. Mixed chimerism predicts graft rejection following BMT for severe aplastic anaemia
70. Immunosuppressive therapy: A potential alternative to bone marrow transplantation as initial therapy for acquired severe aplastic anemia in childhood?
71. The aplastic anaemia-paroxysmal nocturnal haemoglobinuria syndrome
72. Somatic mutations in paroxysmal nocturnal hemoglobinuria: A blessing in disguise?
73. Phenotypic and functional analysis of bone marow progenitor cell compartment in bone marrow failure
74. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia
75. The hematopoietic defect in aplastic anemia assessed by long-term marrow culture
76. Aplastic anaemia following exposure to 3,4-methylene-dioxymethamphetamine ('Ecstacy')
77. Results at a single centre of immunosuppression with cyclosporine A in 66 children with aplastic anaemia
78. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: A report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group
79. Cytogenetic abnormalities in patients with severe aplastic anemia
80. Antithymocyte globulin for patients with myelodysplastic syndrome
81. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia
82. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia
83. Pregnancy and severe aplastic anaemia: Causal relation or coincidence?
84. Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens
85. Prevention of transfusion-transmitted cytomegalovirus infection
86. Clinical characteristics predict response to antithymocyte globulin in paroxysmal nocturnal haemoglobinuria
87. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient
88. Increased apoptosis in aplastic anaemia bone marrow progenitor cells: Possible pathophysiologic significance
89. Secondary solid malignant tumors occurring after bone marrow transplantation for severe aplastic anemia given thoraco-abdominal irradiation
90. Improved prognosis for acquired aplastic anaemia
91. DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1
92. Long-term interleukin-3 and intensive immunosuppression in the treatment of aplastic anemia
93. Standard immunosuppression is superior to cyclosporine/filgrastim in severe aplastic anaemia (Abstract)
94. The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment
95. Unusual complications after bone marrow transplantation for dyskeratosis congenita
96. Intensive immunosuppression with antithymocyte globulin and cyclsporine as treatment for severe acquired aplastic anemia
97. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia
98. Bone marrow transplants for paroxysmal nocturnal haemoglobinuria
99. A pathogenetic link between aplastic anemia and paroxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency phosphatidylinositol glycan anchored proteins
100. Second immunosuppressive treatment of patients with aplastic anemia not responding to the first course of immunosuppression (IS): A report from the Working Party on severe aplastic anemia of the EBMT
101. A phase I/II trial of recombinant human interleukin-6 in patients with aplastic anaemia
102. Guidelines for treating aplastic anemia. Consensus Document of a Group of International Experts
103. Haemopoietic progenitor cells are reduced in aplastic anaemia
104. Molecular typing shows a high level of HLA class I incompatibility in serologically well matched donor/patient pairs: Implications for unrelated bone marrow donor selection
105. Malignant tumors occuring after treatment of aplastic anemia
106. Paroxysmal nocturnal haemoglobinuria: Long-term follow-up and prognostic factors
107. Long-term survival and late deaths after allogeneic bone marrow transplantation
108. Splenectomy as an adjuvant measure in the treatment of severe aplastic anaemia
109. Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection
110. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia
111. Methotrexate and cyclosporine for graft-vs-host disease prevention: What length of therapy with cyclosporine?
112. Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis)
113. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria
114. Late haematological complications in severe aplastic anaemia
115. Late clonal complications in severe aplastic anemia
116. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia
117. Report on a randomized trial comparing cyclophosphamide and cyclosporine vs antithymocyte globulin and cyclosporine as initial treatment for severe aplastic anemia
118. Deficiency of glycosyl-phosphatidylinositol-linked membrane glycoproteins of leukocytes in paroxysmal nocturnal hemoglobinuria, description of a new diagnostic cytofluorometric assay
119. Thrombopoietin: Its role in platelet disorders and as a new drug in clinical medicine
120. Patterns of infection in patients with aplastic anemia and the emergence of aspergillus as a major cause of death
121. Risk factors for interstitial pneumonia following bone marrow transplantation for severe aplastic anaemia
122. Characterization of the CAMPATH-1 (CDw52) antigen: Biochemical analysis and cDNA cloning reveal an unusually small peptide backbone
123. Identification and treatment of late onset Fanconi's anemia